Literature DB >> 19553803

Rationale for combination therapy in age-related macular degeneration.

Richard F Spaide1.   

Abstract

Choroidal neovascularization (CNV) is typically characterized as an invasion of blood vessels, but it is important to recognize concurrent inflammatory and mesenchymal cell infiltration. A two component model of CNV can be thought to be composed of a vascular component and an extravascular component. Macular damage is possible through either. Given the redundancy and complex interaction among biologic systems involved in the production of CNV, it is likely that a monotherapeutic approach will not be fully effective. The vascular component of CNV arises through the orchestrated interaction of a number of growth factors such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), which maintains pericyte viability. The vascular component of CNV can be selectively targeted with anti-VEGF and anti-PDGF drugs or nonselectively with such modalities as ionizing radiation. The extravascular component can be targeted selectively by inhibiting specific cytokines such as tumor necrosis factor alpha or nonselectively with antiinflammatory drugs such as corticosteroids.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19553803     DOI: 10.1097/IAE.0b013e3181ad237a

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  12 in total

1.  Tachyphylaxis during ranibizumab treatment of exudative age-related macular degeneration.

Authors:  Sibel Doguizi; Sengul Ozdek; Selcen Yuksel
Journal:  Int J Ophthalmol       Date:  2015-08-18       Impact factor: 1.779

2.  Intravitreal injection of (99)Tc-MDP inhibits the development of laser-induced choroidal neovascularization in rhesus monkeys.

Authors:  Kunbei Lai; Chenjin Jin; Shu Tu; Yunfan Xiong; Rui Huang; Jian Ge
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-01-05       Impact factor: 3.117

3.  Induction of vascular endothelial growth factor receptor expression in human umbilical vein endothelial cells after repeated bevacizumab treatment in vitro.

Authors:  Ji Eun Lee; Jin Young Kim; Jae Ho Jung; Dong Hoon Shin; Sung Who Park
Journal:  Int J Ophthalmol       Date:  2017-07-18       Impact factor: 1.779

Review 4.  From pathobiology to the targeting of pericytes for the treatment of diabetic retinopathy.

Authors:  Joseph F Arboleda-Velasquez; Cammi N Valdez; Christina K Marko; Patricia A D'Amore
Journal:  Curr Diab Rep       Date:  2015-02       Impact factor: 4.810

5.  Therapeutic potential of intravitreal pharmacotherapy in retinal vein occlusion.

Authors:  Marianne L Shahsuvaryan
Journal:  Int J Ophthalmol       Date:  2012-12-18       Impact factor: 1.779

6.  Comparison of the efficacy of anti-VEGF monotherapy versus PDT and intravitreal anti-VEGF combination treatment in AMD: a Meta-analysis and systematic review.

Authors:  Yao Tong; Ke-Ke Zhao; Dong Feng; Manas Biswal; Pei-Quan Zhao; Zhao-Yang Wang; Yun Zhang
Journal:  Int J Ophthalmol       Date:  2016-07-18       Impact factor: 1.779

7.  Regression of choroidal neovascularization in response to systemic chemotherapy for cancer.

Authors:  Annie W Hsu; Akrit Sodhi; Charles Eberhart; Silvia Montaner; Morton F Goldberg
Journal:  Can J Ophthalmol       Date:  2013-08       Impact factor: 1.882

8.  Pharmacogenetic influence of LOC387715/HTRA1 on the efficacy of bevacizumab treatment for age-related macular degeneration in a Korean population.

Authors:  Haeng Ku Kang; Myung Hun Yoon; Dae Hyun Lee; Hee Seung Chin
Journal:  Korean J Ophthalmol       Date:  2012-11-12

Review 9.  Widening use of dexamethasone implant for the treatment of macular edema.

Authors:  Vincenza Bonfiglio; Michele Reibaldi; Matteo Fallico; Andrea Russo; Alessandra Pizzo; Stefano Fichera; Carlo Rapisarda; Iacopo Macchi; Teresio Avitabile; Antonio Longo
Journal:  Drug Des Devel Ther       Date:  2017-08-16       Impact factor: 4.162

10.  Theme trends and knowledge structure on choroidal neovascularization: a quantitative and co-word analysis.

Authors:  Fangkun Zhao; Bei Shi; Ruixin Liu; Wenkai Zhou; Dong Shi; Jinsong Zhang
Journal:  BMC Ophthalmol       Date:  2018-04-03       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.